An announcement was made today by Novartis that it has successfully acquired Xiidra (lifitegrast ophthalmic solution) 5 percent, which is the first and the exclusive prescription treatment that got approval for the treatment of both the signs, as well as, the symptoms of the dry eye by preventing the inflammation caused by the disease.
The President of Novartis Pharmaceuticals, Maria France Tschudin stated that this deal delivers on their continuing commitment to re-envision the medicine for those patients who are suffering from multiple eye diseases, while also laying the fundamental groundwork for the future, possible front of the eye products which they have in production.
Xiidra is a prescription eye drop solution developed for the treatment of the signs & symptoms of dry eye disease. In each eye, it dosed twice every day, around 12 hours apart. Xiidra has been approved in various markets inclusive of Australia, the United States, and Canada. In numerous markets, it is under regulatory review.
Around 1 thousand patients have received the treatment of Xiidra in 4 device-controlled twelve-week trials. Each of the 4 studies examined the effect of the Xiidra on both the symptom and the signs of the dry eye disease at the baseline, 2nd week, 6th week, and 12th week.
In 3 of the 4 studies, there was an observation of a larger reduction in the eye dryness score (EDS with Xiidra at 6 and 12 weeks. In 2 of the 4 studies, an improvement was observed in the eye dryness score with Xiidra at 2 weeks. At the 12th week, a larger reduction was observed in the inferior corneal staining score (ICSS) favoring Xiidra in 3 of the 4 studies. The most common negative reactions reported in 5-25% of patients were reduced visual acuity, installation site irritation, and altered taste sensation.